Sentinel lymph node biopsy in cutaneous melanoma: Outcome after 5-years follow-up

European Journal of Dermatology

Volumn 17, Issue 5, 2007, Pages 387-391

  Cuchet, Elsa ^a   Pinel, Nicole ^a   Corcella, Denis ^a   Vuillez, Jean Philippe ^a   Lebeau, Jacques ^a   Moutet, François ^a   Colonna, Marc ^a   Leccia, Marie Thérèse ^a  

^a HÔPITAL MICHALLON   (France)

Author keywords

Lymphadenectomy; Melanoma; Overall survival; Recurrence free survival; Safe procedure; Sentinel node

Indexed keywords

TECHNETIUM 99M;

ADULT; ARTICLE; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MELANOMA; OUTCOME ASSESSMENT; SENTINEL LYMPH NODE BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 34548731327     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: 10.1684/ejd.2007.0235     Document Type: Article

References (24)

1. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19(16): 3635-4.
2. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19(16): 3622-34.
3. Trost O, Danino AM, Dalac S, Herve C, Moutel G, Malka G. [Is sentinel l ymph node procedure in early-staged cutaneous melanoma really safe?]. Ann Chir Plast Esthet 2005; 50(2): 113-7.
4. McMasters KM, Reintgen DS, Ross MI, et al. Sentinel lymph node biopsy for melanoma: now many radioactive nodes should be removed? Ann Surg Oncol 2001; 8(3): 192-7.
5. Blumenthal R, Banic A, Brand CU, Ris HB, Lardinois D. Morbidity and outcome after sentinel lymph node dissection in patients with early-stage malignant cutaneous melanoma. Swiss Surg 2002; 8(5): 209-14.
6. Jansen L, Nieweg OE, Peterse JL, Hoefnagel CA, Olmos RA, Kroon BB. Reliability of sentinel lymph node biopsy for staging melanoma. Br J Surg 2000; 87(4): 484-9.
7. Morton DL, Cochran AJ, Thompson JF, et al. Sentinel node biopsy for early- stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg 2005; 242(3): 302-11; (discussion 311-3).
8. Jacobs IA, Chevinsky AH, Swayne LC, Magidson JG, Britto EJ, Smith TJ. Gamma probe-directed lymphatic mapping and sentinel lymphadenectomy in primary melanoma: Reliability of the procedure and analysis of failures after long-term follow- up. J Surg Oncol 2001; 77(3): 157-64.
9. Doting MH, Hoekstra HJ, Plukker JT, et al. Is sentinel node biopsy beneficial in melanoma patients? A report on 200 patients with cutaneous melanoma. Eur J Surg Oncol 2002; 28(6): 673-8.
10. Berk DR, Johnson DL, Uzieblo A, Kiernan M, Swetter SM. Sentinel lymph node biopsy for cutaneous melanoma: the Stanford experience, 1997-2004. Arch Dermatol 2005; 141(8): 1016-22.
11. Morton DL, Thompson JF, Essner R, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg 1999; 230(4): 453-63; (discussion 463-5).
12. Gershenwald JE, Colome MI, Lee JE, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998; 16(6): 2253-60.
13. Messina JL, Glass LF, Cruse CW, Berman C, Ku NK, Reintgen DS. Pathologic examination of the sentinel lymph node in malignant melanoma. Am J Surg Pathol 1999; 23(6): 686-90.
14. Shivers SC, Wang X, Li W, Joseph E, et al. Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA 1998; 280(16): 1410-5.
15. Blaheta HJ, Ellwanger U, Schittek B, et al. Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma. J Invest Dermatol 2000; 114(4): 637-42.
16. Rimoldi D, Lemoine R, Kurt AM, et al. Detection of micrometastases in sentinel lymph nodes from melanoma patients: direct comparison of multimarker molecular and immunopathological methods. Melanoma Res 2003; 13(5): 511-20.
17. 99mTc-MIBI scintigraphy and sentinel node biopsy in the detection of occult lymph node metastases from cutaneous melanoma. Eur J Dermatol 2003; 13(5): 449-54.
18. Ranieri JM, Wagner JD, Azuaje R, et al. Prognostic importance of lymph node tumor burden in melanoma patients staged by sentinel node biopsy. Ann Surg Oncol 2002; 9(10): 975-81.
19. Carlson GW, Murray DR, Lyles RH, Staley CA, Hestley A, Cohen C. The amount of metastatic melanoma in a sentinel lymph node: does it have prognostic significance? Ann Surg Oncol 2003; 10(5): 575-81.
20. Statius Muller MG, van Leeuwen PA, de Lange-De Klerk ES, et al. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma. Cancer 2001; 91(12): 2401-8.
21. Liszkay G, Peley G, Sinkovics I, et al. Clinical significance of sentinel lymph node involvement in malignant melanoma. Pathol Oncol Res 2003; 9(3): 184-7.
22. Morton D, Thompson J, Cochran A, et al. Sentinel-Node Biopsy or Nodal Observation in Melanoma. N Engl J Med 2006; 335(13): 1307-17.
23. Woods GM, Malley RC, Muller HK. The skin immune system and the challenge of tumour immunosurveillance. Eur J Dermatol 2005; 15(2): 63-9.
24. Vuylsteke RJ, Borgstein PJ, van Leeuwen PA, et al. Sentinel lymph node tumor load: an independent predictor of additional lymph node involvement and survival in melanoma. Surg Oncol 2005; 12(6): 1-9.